AN INNOVATIVE TARGETED ONCOLOGY COMPANY BUILT ON NEXT GENERATION ANTIBODY-DRUG CONJUGATES (ADC) AND A NOVEL DISCOVERY ENGINE
Announced Securities Purchase Agreement For Up To $20 Million with Aspire Capital Fund, LLC NEW YORK and LONDON, September 27, 2018 - Akari Therapeutics, Plc …
[Read more...] about Akari Announces Second Quarter 2018 Financial Results and Business Highlights
Combined inhibition of LTB4 and C5 by Coversin showed reversal of disease symptoms in preclinical rheumatoid arthritis (RA) model Ex vivo data from bullous …
Notice of Annual Shareholders Meeting 2018 Proxy Form Dear Shareholders of Akari Therapeutics, Plc: You are cordially invited to attend (and …
[Read more...] about Notice of Annual Shareholders Meeting & Proxy Form
Opened three clinical trials in 2018 Trials in which complement dysregulation is the primary disease driver CAPSTONE, the Phase III trial in naïve …
NEW YORK and LONDON, June 15, 2018 - Akari Therapeutics, Plc (NASDAQ:AKTX), a biopharmaceutical company focused on the development and commercialization of …
